

Paediatric patients transplanted between 2000 and 2016


Patient Characteristics		N	%
Total number of HSCT		61112	
Total number of patients		52665	
Ratio HSCT/Patients		1,16	
Median age in years at diagnosis (Min-Max)		4.91(0-17.9)	
Median age in years at HSCT (Min-Max)		7.61(0-17.9)	
Gender	Male	31326	59.5
	Female	21077	40.2
Diagnosis	Malignant diseases		
	Acute leukaemia	17850	33.9
	Chronic leukaemia	827	1.6
	Lymphoma	3298	6.3
	Plasma cell disorders	29	0.1
	Solid tumours	12232	23.2
	Myelodysplastic/Myeloproliferative	2499	4.7
	Non Malignant diseases		
	Bone marrow failure	4688	8.9
	Inherited disorders	6135	11.7
	Histiocytic disorders	1036	2.0
	Auto-immune diseases	209	0.4
	Hemoglobinopathies	3817	7.3

Transplant Characteristics		Malignant	%	Non-malignant disease	%
Conditioning regimen	MAC	18086	93.8	10237	77.3
	Non-myeloablative	1203	6.2	3014	22.7
	Missing	17446		2634	
Type of transplant	Allogeneic	21033	57.3	15647	98.5
	Autologous	15700	42.7	236	1.5
	Missing	1		2	
Type of cells	BM	12616	34.7	9874	62.9
	PB	20760	57.1	3795	24.2
	CB	2079	5.7	1666	10.6
	Combined	847	2.5	366	2.3
	Missing	382		175	
Type of donors (alloHSCT)	Identical sibling	7051	34.6	6716	43.6
	Relative	2682	13.2	2625	17.0
	Unrelated	10650	52.2	6069	39.4
TBI (age above 2 years old)	No	22840	71.8	10334	95.2
	Yes	8990	28.2	523	4.8
	Missing	1637		452	


Outcome Data I		Malignant diseases	%	Non malignant diseases	%
Status at last follow up. n	Dead	13055	36.5	2836	18.3
	Alive	21126	59.1	11715	75.6
	Lost to follow up	1553	4.3	926	6
	Missing	993		390	
	Chronic GVHD				
Chronic GVHD	No	11565	75.8	9290	85.3
	Yes	3689	24.2	1603	14.7
	Missing	21481		4992	

Outcome Data II		Malignant diseases	%	Non-malignant disease	%
Cause of death	Relapse or progression	8067	65.8	277	10.5
	Secondary malignancy	93	0.8	23	0.9
	HSCT related	3647	29.7	2008	76.1
	Cell therapy(non HSCT)	0	0	3	0.1
	Other	458	3.7	329	12.5
	Missing	790		196	


Number and type of HSCT for non-malignant diseases from 2000-2016



Number and type of HSCT for malignant diseases from 2000-2016



OS from first graft in malignant* and non-malignant diseases



Please send of your proposal of study to us!

- 1) The proposal form can be either requested from the WP secretary or can be retrieved from the EBMT website of the PDWP.
- 2) Completed proposal forms should then be emailed to the PDWP chair, vice-chair, the secretary, and the Clinical Trials Committee chair Marc Ansari (Marc.Ansari@hcuge.ch)

*Plasma cell disorders were not shown in these graphs